PT - JOURNAL ARTICLE AU - P. Barlow AU - L. Allen TI - The impact of trade and investment agreements on the implementation non-communicable disease policies, 2014-2019: protocol for a statistical study AID - 10.1101/2022.05.13.22274669 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.13.22274669 4099 - http://medrxiv.org/content/early/2022/05/16/2022.05.13.22274669.short 4100 - http://medrxiv.org/content/early/2022/05/16/2022.05.13.22274669.full AB - Introduction Regulating tobacco, alcohol, and unhealthy foods and drinks is a cornerstone of global efforts to combat the Non-Communicable Disease (NCD) pandemic, but implementation of these policies remains slow. It has been suggested that producers of these unhealthy commodities use rules in Trade and Investment Agreements (TIAs) to delay and undermine NCD policy implementation. Yet, there is no systematic empirical evidence linking TIA participation to reduced implementation. Here we present a study protocol for a statistical analysis of the relationship between TIA participation and the implementation of regulations on tobacco, alcohol, and unhealthy food and drink in 154 countries, 2014-2019.Methods and analysis We aim to examine whether participation in TIAs with the EU and US is associated with implementation of regulations targeting tobacco, alcohol, and unhealthy food and drink. We focus on TIAs with these countries as their TIAs create multiple opportunities to contest health regulations, and a majority of the major unhealthy commodity producers are registered in these jurisdictions. Partial and full implementation is captured in a recently published dataset which systematically coded implementation of 11 NCD policies in 2014, 2016 and 2019. We will combine these outcome data with TIA membership and covariate data from multiple sources. We will calculate descriptive statistics and use both regression adjustment and matching to conduct covariate-adjusted, quasi-experimental comparisons of implementation levels and progress according to whether or not countries have a TIA with the EU or US. Further analyses and robustness checks will examine additional TIA participation arrangements and test the sensitivity of our results to our model specifications.Ethics and dissemination Ethics approval will not be required as the study uses anonymised and pre-aggregated data. Findings will be disseminated to policymakers via personal contacts and press releases in parallel with scientific papers and conference presentations.Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced will be available upon reasonable request to the authors